Sucampo Pharmaceuticals, Inc. $300 Million Convertible Senior Notes Offering

Ambrogio Visconti

Davis Polk advised the sole book-running manager and initial purchaser in connection with a Rule 144A offering by Sucampo Pharmaceuticals, Inc. of $300 million aggregate principal…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

…

This content is for Standard 1 Year members only.
Login Join Now